Head-to-head

Acetyl-L-carnitine vs Alpha-GPC

Two cholinergic-adjacent cognitive supplements with real dementia-population trial data — and the same gap between where they were studied and who actually buys them.

Acetyl-L-carnitine

ALCAR, levacecarnine

Clinical data

Real RCT data across three separate conditions, unusually deep for this bench — a large pooled effect for depression augmentation, a Cochrane 'very low certainty' verdict for diabetic neuropathy despite two positive trials, and an unsettled, decades-old literature for mild cognitive impairment.

Full Acetyl-L-carnitine evidence review

Alpha-GPC

Choline alfoscerate, choline alphoscerate, L-alpha-glycerylphosphorylcholine

Clinical data

Its strongest human evidence is a randomized dementia trial and an add-on Alzheimer's trial (ASCOMALVA) — not the healthy 'nootropic' population that drives most sales. A 2021 observational analysis also flagged an association with increased 10-year stroke risk that remains unresolved, an open question for anyone with cardiovascular risk factors.

Full Alpha-GPC evidence review

Side by side

	Acetyl-L-carnitine	Alpha-GPC
Marketed for	Cognitive function, mood, diabetic neuropathy, mitochondrial energy	Cognitive enhancement / nootropic use, dementia adjunct
Evidence grade	Clinical data	Clinical data
Family	NAD⁺ & mitochondrial	mTOR & other
Key human source	Veronese 2018 depression meta-analysis, Psychosom Med	De Jesus Moreno Moreno 2003 RCT, Clin Ther

marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Our verdict

Both have their strongest human evidence in dementia and mood-disorder populations, not the healthy 'nootropic' users who drive most sales. Acetyl-L-carnitine has a large pooled effect for depression augmentation and mixed, low-certainty data for diabetic neuropathy. Alpha-GPC has a positive randomized Alzheimer's trial and an add-on benefit alongside donepezil (ASCOMALVA), but also an unresolved 2021 observational stroke-risk signal that acetyl-L-carnitine does not carry.

Acetyl-L-carnitine fits if

Mood or nerve-related symptoms are the target, or you'd rather avoid alpha-GPC's unresolved stroke-risk signal.

Alpha-GPC fits if

Cognitive/dementia-adjacent support is the goal specifically, and you don't have elevated cardiovascular risk factors.